Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

A series of cases with rare thromboembolic incidents including cerebral sinus vein
thrombosis (some of them fatal) and concomitant thrombocytopenia occurring shortly after …

Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …

Background Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
may increase platelet counts in patients with immune thrombocytopenia by means of dual …

Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …

Simple Summary The availability of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has
undoubtedly reshaped the initial management of chronic lymphocytic leukemia (CLL) …

The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the management of
patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects …

C-type lectin-like receptor 2 (CLEC-2, also known as CLEC-1b) is expressed on platelets,
Kupffer cells and other immune cells, and binds to various ligands including the mucin-like …

The prevention and treatment of arterial thrombosis continue to be clinically challenging,
and understanding the relevant molecular mechanisms in detail may facilitate the quest to …

Bruton's tyrosine kinase (BTK) was discovered due to its importance in B cell development,
and it has a critical role in signal transduction downstream of the B cell receptor (BCR) …